Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Vallet

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Blood|March 27, 2007
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, et al.
Blood|May 28, 2010
PI3K/p110{delta} is a novel therapeutic target in multiple myelomaHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
The Journal of Clinical Investigation|January 26, 2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceSiddhartha Mukherjee, Noopur Raje, Jesse A Schoonmaker, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
European Urology Open Science|July 11, 2022
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant ChemotherapyDavid D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Blood|March 27, 2007
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, et al.
Blood|May 28, 2010
PI3K/p110{delta} is a novel therapeutic target in multiple myelomaHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
The Journal of Clinical Investigation|January 26, 2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceSiddhartha Mukherjee, Noopur Raje, Jesse A Schoonmaker, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
European Urology Open Science|July 11, 2022
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant ChemotherapyDavid D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Pageof 8